355 resources
By Version
By Authority
By Realm
Rows 0 - 200 Next
Package | Version | Identity | Name/Title | Status | FMM | WG | Date | Realm | Auth |
---|---|---|---|---|---|---|---|---|---|
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-CPR-1 | Bystander Chest Compressions | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-CPR-10 | TBD | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-CPR-2 | Dispatch coached chest compressions | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-CPR-3 | Time from PSAP to initial compressions | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-CPR-4 | Time to initial shock | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-CPR-5 | Average chest compression rate | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-CPR-6 | Average chest compression depth | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-CPR-7 | Return of Spontaneous Circulation (ROSC)during EMS care | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-CPR-8 | Survival of OHCA with all presenting rhythms | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-CPR-9 | Survival of OHCA when witnessed by bystander | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Hypoglycemia-01 | Treatment Administered for Hypoglycemia | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Hypoglycemia-02 | Improved Post-Treatment Condition | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Hypoglycemia-03 | Hypoglycemic Patients Treated and not Transported | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Hypoglycemia-04 | Repeat Response for Patient Previously Not Transported | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Opioid-01 | Percentage of suspected opioid OD patients who received Narcan | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Opioid-02 | Percentage of suspected opioid OD patients transported to an ED | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Opioid-03 | Percentage of suspected opioid OD patients given multiple Narcan doses in case of an “Unchanged” response to the first dose | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Opioid-04 | Percentage of suspected opioid OD patients experiencing a repeat OD within a specified time period. | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Opioid-05 | Percentage of suspected opioid OD patients with a recorded combination of altered mental status, poor respiratory effort (RR<12 per minute), and pin point pupils. | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Opioid-06 | Percentage of suspected opioid OD patients with a specific opioid recorded | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Opioid-07 | Percentage of suspected opioid OD patients experiencing an Increase in pulse oximetry after EMS care. | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Opioid-08 | Percentage of suspected opioid OD patients experiencing an Increase in Glasgow Coma Scale (GCS) after EMS care. | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Opioid-09 | Percentage of suspected opioid OD patients experiencing an Increase in respiratory rate after EMS care. | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Opioid-10 | Percentage of suspected opioid OD patients who received ventilatory support within five minutes of first EMS unit’s arrival on scene. | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Opioid-11 | Percentage of suspected opioid OD patients experiencing who exhibit adverse effects after naloxone administration | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-PEDS-01 | Respiratory Assessment - Pediatric | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-PEDS-02 | Administration of beta agonist for pediatric asthma | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-PEDS-03 | Documentation of estimated weight in kilograms - pediatric | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-PEDS-04 | Medication error rate | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-STEMI-1 | Time to first EKG | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-STEMI-2 | Time to receiving facility pre-notification | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-STEMI-3 | Transport to PCI/Thrombolytic capable facilities | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-STEMI-4 | Time from First medical contact to receiving facility | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-STEMI-5 | Patients with complete bundle of care | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-STEMI-6 | EMS correctly identified STEMI | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-STEMI-7 | Time to Reperfusion | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Safety-01 | Lights and Sirens Response to Scene Rate | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Safety-02 | Lights and Sirens Transport Rate | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Safety-03 | Number of crashes | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Safety-04 | Number of crashes resulting in injury | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Safety-05 | Number of fatal crashes | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Safety-06 | Rate of crashes per 100,000mi | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Safety-07 | Rate of crashes resulting in injury per 100,000mi | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Safety-08 | Rate of fatalities per 100,000mi | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Seizure-01 | Blood Glucose Evaluation | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Seizure-02 | Patient Received Intervention | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Seizure-03 | Patients with Terminated Seizures | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Stroke-01 | Suspected Stroke Receiving Prehospital Stroke Assessment | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Stroke-02 | Blood Glucose Measurement for Patients with a Provider Impression of Stroke | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Stroke-03 | Prehospital Notification | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Stroke-04 | Positive Stroke Assessments Transported to a Hospital Verified, Designated or Otherwise Identified as Acute Stroke-Ready or Higher | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Stroke-05 | Provider Impression of Stroke with Last Known Well (LKW) Documented | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Stroke-06 | Prehospital Stroke Care Bundle | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Stroke-07 | For Patients with Positive Stroke Assessment, Average Time from Last Known Well to Arrival at a Hospital Verified, Designated or Otherwise Identified as Acute Stroke-Ready or Higher | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Stroke-08 | Emergency Department Diagnosed Stroke Identified by Prehospital Stroke Assessment | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Trauma-01 | Pain assessment of injured patients | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Trauma-02 | Pain re-assessment of injured patients | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Trauma-03 | Effectiveness of pain management for injured patients | unknown | 2024-10 | uv | ihe | ||
ihe.qrph.qore | R4 | Measure/example-IHE-QORE-Trauma-04 | Trauma patients transported to trauma center | unknown | 2024-10 | uv | ihe | ||
ihe.palm.rpc | R4 | Measure/MeasureBreastDistanceFromTheNipple | Breast Distance from the Nipple Rad Path Correlation | draft | 2023-06 | uv | ihe | ||
ihe.palm.rpc | R4 | Measure/MeasureBreastLaterality | Breast Laterality Rad Path Correlation | draft | 2023-06 | uv | ihe | ||
ihe.palm.rpc | R4 | Measure/MeasureBreastLocationOfLesion | Breast Location of Lesion Rad Path Correlation | draft | 2023-06 | uv | ihe | ||
ihe.palm.rpc | R4 | Measure/MeasureBreastQuadrantAndClockFace | Breast Quadrant and Clock Face Rad Path Correlation | draft | 2023-06 | uv | ihe | ||
ihe.palm.rpc | R4 | Measure/MeasureGleason | Gleason Score Rad Path Correlation | draft | 2023-06 | uv | ihe | ||
ihe.palm.rpc | R4 | Measure/MeasureProstateLesionSize | Prostate Lesion Size Rad Path Correlation | draft | 2023-06 | uv | ihe | ||
ihe.palm.rpc | R4 | Measure/MeasureProstateSize | Prostate Size Rad Path Correlation | draft | 2023-06 | uv | ihe | ||
ihe.palm.rpc | R4 | Measure/MeasureProstateTumorLocation | Prostate Tumor Location Rad Path Correlation | draft | 2023-06 | uv | ihe | ||
smart.who.int.hiv | R4 | Measure/HIVIND35 | HIV.IND.35 ARV toxicity prevalence | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND41 | HIV.IND.41 ART coverage in breastfeeding mothers | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND39 | HIV.IND.39 Infant ARV prophylaxis coverage | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND38 | HIV.IND.38 Early infant diagnosis (EID) coverage | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND42 | HIV.IND.42 Final outcome of PMTCT | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND37 | HIV.IND.37 Viral suppression at labour and delivery | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND40 | HIV.IND.40 ART coverage in pregnant women | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND14 | HIV.IND.14 OAMT minimum dose | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND13 | HIV.IND.13 OAMT minimum duration | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND6 | HIV.IND.6 PEP completion | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND7 | HIV.IND.7 HIV in PEP recipients | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND11 | HIV.IND.11 OAMT coverage | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND76 | HIV.IND.76 Presence of STI syndrome, HIV prevention services | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND78 | HIV.IND.78 Repeat diagnosis of STI syndrome, HIV prevention services | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND70 | HIV.IND.70 Gonorrhoea testing coverage, HIV prevention services | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND74 | HIV.IND.74 Gonorrhoea treatment coverage, HIV prevention services | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND66 | HIV.IND.66 Syphilis treatment coverage, HIV prevention services | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND83 | HIV.IND.83 HCV test coverage, HIV prevention services | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND80 | HIV.IND.80 HBV test coverage, HIV prevention services | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND62 | HIV.IND.62 Syphilis test positivity, HIV prevention services | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND58 | HIV.IND.58 Syphilis testing coverage, HIV prevention services | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND88 | HIV.IND.88 HCV positivity, HIV prevention services | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND53 | HIV.IND.53 Multi-month ARV dispensing | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND92 | HIV.IND.92 HCV cured among people living with HIV | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND90 | HIV.IND.90 HBV treatment among people living with HIV | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND91 | HIV.IND.91 HCV treatment among people living with HIV | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND77 | HIV.IND.77 Presence of STI syndrome, HIV-positive clients | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND79 | HIV.IND.79 Repeat diagnosis of STI syndrome, HIV-positive clients | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND57 | HIV.IND.57 Viral suppression among people living with HIV engaged in DSD ART models | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND55 | HIV.IND.55 Coverage of DSD ART models among people living with HIV on ART | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND52 | HIV.IND.52 TB treatment initiation among diagnosed | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND50 | HIV.IND.50 TB testing among those symptom-screened positive | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND51 | HIV.IND.51 TB diagnosis among those tested for TB | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND47 | HIV.IND.47 People living with HIV with active TB disease | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND48 | HIV.IND.48 TB screening coverage among new ART patients | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND49 | HIV.IND.49 TB symptom-screened positive among new ART patients | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND29 | HIV.IND.29 People living with HIV on ART who have suppressed viral load | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND32 | HIV.IND.32 Viral load testing coverage | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND34 | HIV.IND.34 Appropriate second viral load test after adherence counselling | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND71 | HIV.IND.71 Gonorrhoea testing coverage, HIV-positive clients | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND75 | HIV.IND.75 Gonorrhoea treatment coverage, HIV-positive clients | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND67 | HIV.IND.67 Syphilis treatment coverage, HIV-positive clients | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND31 | HIV.IND.31 Late ART initiation | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND73 | HIV.IND.73 Gonorrhoea test positivity, HIV-positive clients | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND84 | HIV.IND.84 HCV test coverage, HIV-positive clients | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND81 | HIV.IND.81 HBV test coverage, HIV-positive clients | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND63 | HIV.IND.63 Syphilis test positivity, HIV-positive clients | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND59 | HIV.IND.59 Syphilis testing coverage, HIV-positive clients | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND46 | HIV.IND.46 TB diagnostic testing type | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND89 | HIV.IND.89 HCV positivity, HIV-positive clients | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND21 | HIV.IND.21 Linkage to ART | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND54 | HIV.IND.54 Uptake of DSD ART models among people living with HIV | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND3 | HIV.IND.3 PrEP coverage | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND56 | HIV.IND.56 Retention in DSD ART models | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND25 | HIV.IND.25 HIV retesting coverage | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND9 | HIV.IND.9 Regular NSP access | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND8 | HIV.IND.8 NSP coverage | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND72 | HIV.IND.72 Gonorrhoea test positivity, HIV prevention services | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND12 | HIV.IND.12 Total person-years on OAMT | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND68 | HIV.IND.68 Syphilis treatment coverage, pregnant women, first ANC visit | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND43 | HIV.IND.43 HIV prevalence among women attending ANC | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND64 | HIV.IND.64 Syphilis test positivity, pregnant women, first visit | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND65 | HIV.IND.65 Syphilis test positivity, pregnant women, any visit | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND69 | HIV.IND.69 Syphilis treatment coverage, pregnant women, any ANC visit | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND82 | HIV.IND.82 HBV test coverage, pregnant women | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND61 | HIV.IND.61 Syphilis testing coverage, pregnant women, any ANC visit | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND60 | HIV.IND.60 Syphilis testing coverage, pregnant women, first ANC visit | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND95 | HIV.IND.95 Invasive cervical cancer treatment | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND94 | HIV.IND.94 Pre-invasive cervical disease treatment | draft | 2024-08 | who | |||
smart.who.int.hiv | R4 | Measure/HIVIND20 | HIV.IND.20 Individuals testing positive for HIV | draft | 2024-08 | who | |||
hl7.fhir.us.davinci-deqm | R4 | Measure/measure-mrp-example | MRP Measure | active | 2019-12 | us | hl7 | ||
hl7.fhir.uv.cqm | R4 | Measure/measure-cqm-publishable-example | Measure CQM Publishable Example | active | 2025-07 | uv | hl7 | ||
hl7.fhir.uv.cqm | R4 | Measure/age-stratified-example | Measure Age Stratified Example | active | 2025-08 | uv | hl7 | ||
smart.who.int.hiv | R4 | Measure/HIVIND24 | HIV.IND.24 HTS linkage to prevention | draft | 2024-08 | who | |||
hl7.fhir.uv.cqm | R4 | Measure/measure-pi-exm | EXM Promoting Interoperability Measure | active | 2023-05 | uv | hl7 | ||
hl7.fhir.uv.cqm | R4 | Measure/EXMLogic-FHIR | EXM Measure | active | 2025-08 | uv | hl7 | ||
hl7.fhir.us.cqfmeasures | R4 | Measure/EXMLogic-FHIR | EXM Measure | active | 2022-02 | us | hl7 | ||
hl7.fhir.uv.cqm | R4 | Measure/EXMRatio-FHIR | EXM Ratio Measure | active | 2025-08 | uv | hl7 | ||
hl7.fhir.uv.cqm | R4 | Measure/measure-publishable-exm | EXM Publishable Measure | active | cqi | 2025-08 | uv | hl7 | |
hl7.fhir.us.davinci-deqm | R4 | Measure/measure-pi-example | EXM Promoting Interoperability Measure | active | 2023-05 | us | hl7 | ||
hl7.fhir.uv.cpg | R4 | Measure/chf-bodyweight-change-measure | CHF Body Weight Change Metric | active | 2024-11 | uv | hl7 | ||
hl7.fhir.uv.cpg | R4 | Measure/chf-bodyweight-measure | CHF Body Weight Metric | active | 2024-11 | uv | hl7 | ||
smart.who.int.hiv | R4 | Measure/HIVIND96 | HIV.IND.96 Cervical cancer survival | draft | 2024-08 | who | |||
example.fhir.uv.mycontentig | R4 | Measure/HRExampleCVMeasure | HR Example CV (Measure Name in Details Tab of MADiE UI) | draft | 2025-08 | uv | hl7 | ||
example.fhir.uv.mycontentig | R4 | Measure/HRExampleCohortMeasure | HR Example Cohort (Measure Name in Details Tab of MADiE UI) | draft | 2025-08 | uv | hl7 | ||
example.fhir.uv.mycontentig | R4 | Measure/HRExampleProportionMeasure | HR Example Proportion (Measure Name in Details Tab of MADiE UI) | draft | 2025-08 | uv | hl7 | ||
example.fhir.uv.mycontentig | R4 | Measure/HRExampleRatioMeasure | HR Example Ratio (Measure Name in Details Tab of MADiE UI) | draft | 2025-08 | uv | hl7 | ||
hl7.fhir.us.davinci-vbpr | R4 | Measure/vbp-measure02 | Example Value-Based Contract - ABC Payer and EveryHospital | active | 2025-07 | us | hl7 | ||
hl7.fhir.us.davinci-vbpr | R4 | Measure/vbp-measure01 | Example Value-Based Contract - ABC Payer and GoodHealth | active | 2025-07 | us | hl7 | ||
hl7.fhir.uv.cpg | R4 | Measure/activity-example-generatereport-measure | Activity Example Generate Report Measure | active | 2023-10 | uv | hl7 | ||
example.fhir.uv.mycontentig | R4 | Measure/QuestionnaireMeasureExample | Questionnaire Measure Example | draft | 2025-08 | uv | hl7 | ||
hl7.fhir.us.davinci-ra | R4 | Measure/RAModelExample02 | Risk Adjustment Model Version 21 - CMS Hierarchical Category Condition (CMS-HCC) | active | 2021-09 | us | hl7 | ||
hl7.fhir.us.davinci-ra | R4 | Measure/RAModelExample01 | Risk Adjustment Model Version 24 - CMS Hierarchical Category Condition (CMS-HCC) | active | 2021-08 | us | hl7 | ||
hl7.fhir.us.davinci-ra | R4 | Measure/RAModelExample03 | Risk Adjustment Model Version 5 - CMS Prescribing Drug Hierarchical Category Condition (CMS-RxHCC) | active | 2021-09 | us | hl7 | ||
hl7.fhir.us.safr | R4 | Measure/HospitalRespiratoryDataMeasure | Measure - HRD Measure Example | draft | 2024-12 | us | hl7 | ||
ihe.qrph.madx | R4 | Measure/madx-hiv-indicator-example1 | mADX-Measure-example1 | draft | 2024-08 | uv | ihe | ||
ihe.qrph.madx | R4 | Measure/madx-hiv-indicator-example2 | mADX-Measure-example2 | draft | 2024-08 | uv | ihe | ||
smart.who.int.immunizations | R4 | Measure/IMMZIND01 | IMMZIND01 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND02 | IMMZIND02 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND03 | IMMZIND03 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND04 | IMMZIND04 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND05 | IMMZIND05 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND06 | IMMZIND06 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND07 | IMMZIND07 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND08 | IMMZIND08 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND09 | IMMZIND09 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND10 | IMMZIND10 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND11 | IMMZIND11 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND12 | IMMZIND12 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND13 | IMMZIND13 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND14 | IMMZIND14 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND15 | IMMZIND15 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND16 | IMMZIND16 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND17 | IMMZIND17 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND18 | IMMZIND18 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND19 | IMMZIND19 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND20 | IMMZIND20 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND21 | IMMZIND21 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND22 | IMMZIND22 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND23 | IMMZIND23 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND24 | IMMZIND24 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND25 | IMMZIND25 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND26 | IMMZIND26 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND27 | IMMZIND27 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND28 | IMMZIND28 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND29 | IMMZIND29 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND30 | IMMZIND30 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND31 | IMMZIND31 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND32 | IMMZIND32 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND33 | IMMZIND33 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND34 | IMMZIND34 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND35 | IMMZIND35 | draft | 2025-06 | who | |||
smart.who.int.immunizations | R4 | Measure/IMMZIND36 | IMMZIND36 | draft | 2025-06 | who |